Brucellosis is a zoonotic disease caused by Brucella spp., namely B. meletinsis and B. abortus 22
Brucella spp. is a Gram-negative coccobacillus that causes Brucellosis (also known as 41 "Malta fever"); a contagious zoonotic infectious disease (1). The genus Brucella consists of 42 seven species, four of which causes a disease in humans. The most common species include 43 B. melitensis which is transmitted from goat and sheep followed by B. abortus that comes from 44 cows. B. suis has a more restricted occurrence and is transmitted from pigs. Lastly, B. canis is 45 uncommonly associated with human diseases but can be transmitted from dogs (2, 3). 46
Brucellosis patients usually acquire the disease through consumption of unpasteurized dairy 47 products or direct contact with infected animals or their fluids (4). The infection usually starts 48 with nonspecific symptoms, such as fatigue, headache, dry cough, and night sweats (2). 49
However, in severe cases it can be associated with variable complications (2). 50
To aid the clinical diagnosis of brucellosis, laboratory methods are utilized which include 51 direct and indirect methods. Direct methods include microbiological culturing as well as the 52 detection Brucella gene using polymerase chain reaction (PCR) test (1). Brucella culture is 53 considered the gold standard and provides the definitive diagnosis of the disease (5). However, 54
as Brucella is a slow-growing bacterium, it may take the culture a week or longer to show 55 growth (6). Additionally, patients with a long-standing disease may have negative culture results. 56 Therefore, indirect serological assays are used alternatively and provide faster results. The Rose 57
Bengal testing, tube agglutination, and enzyme-linked immunosorbent assay (ELISA) are the 58 most recommended methods of Brucella serology (1). Moreover, some nonspecific laboratory 59 tests, such as white blood cell (WBC) count, C-reactive protein (CRP), erythrocyte 60 sedimentation rate (ESR), serum lactate dehydrogenase, and alkaline phosphatase may show 61 some changes (6). 62 4 In a response to an infection with Brucella spp., the immune system naturally produces 63 antibodies. IgM isotype is first produced followed by the IgG and IgA isotypes. With appropriate 64 treatment, the titer of these antibodies should gradually fall off. The remaining high titer of IgG 65
and IgA indicate a possibility of relapse or progress to a chronic focal disease (2). 66 A retrospective study of brucellosis patients showed that Brucella antibodies remained 67 persistently positive even after the patients demonstrated full clinical recovery and cure (7). As 68 serological cure of brucellosis is defined when antibody titers reach less than 1:320, the rate of 69 serological cure in this study increased from 8.3% in the first three months to 71.4% after two or 70 more years with a median time for a serological cure of 18.5 ± 3 months. In addition, none of the 71 116 patients included in the study experienced a relapse at the end of the follow up period 72 although some patients did not achieve the serological cure Out of 695 patients who tested for Brucella via serology or culture, only 94 had positive 108 serology and were diagnosed with brucellosis. Table 1 lists the characteristics of patients  109 included in the study. More than half of the patients were males with an average age of 48 ± 19 110 years. Overall, patients did not have fever or leukocytosis at baseline; though, CRP levels and 111 ESR were mostly elevated. In addition, less than one-third of the patients had complicated 112 brucellosis or arthralgia. Sixty three of the 94 patients included in the study had EOT serological 113 results available. Median antibody titers at EOT were lower than their baseline counterparts. 114
Similarly, median CRP level and ESR showed a decrease from baseline. The majority of patients 115 experienced clinical cure and only 5 died. 116
The correlations between EOT Brucella antibody titers with different outcome variables 117 are shown in Table 2 . Table 3 shows the correlation after stratifying the antibody titers based on 118 the serological cure criterion of < 1:320. A significant, though weak, correlation between clinical 119 cure and low EOT antibody titers of both Brucella spp. was found. Nevertheless, this correlation 120 was lost when antibody titers were stratified based on the cutoff value of 1:320. This can be 121 further recognized in Figure 1 where almost equal rates of clinical cure and failure was observed 122 in the subgroup of patients who had EOT antibody titers of < 1:320. Furthermore, no significant 123 correlations were found between EOT antibody titers of either Brucella spp. and other outcomes 124 except for EOT WBC count where lower B. abortus antibody titers only were weakly associated 125 with higher WBC counts (negative correlation). Interestingly, such correlation turned towards 126 the opposite direction after the stratification based on the serological cure cutoff. In addition of 127 both of these correlations with EOT WBC counts being weak as represented by the low 128 correlation coefficient, patients generally had normal mean WBC count at this time point. 129 7 Subgroup analyses of patients with uncomplicated or complicated brucellosis showed similar 130 results of lack of correlation between the EOT antibody titers and all of the tested variables. 131 Table 4 and Table 5 list the correlation results of different baseline variables with  132 baseline antibody titers before and after stratification based on the serological criterion for 133 diagnosis of ≥ 1:640, respectively. While it seems that the antibody titers of B. abortus correlate 134 with culture positivity in both tables, this correlation can be considered weak with the low value 135 of the correlation coefficient, as well as by visualizing the lack of difference in the rate of culture 136 positivity among patients who met the serological diagnostic criterion at baseline (Figure 2) . 137
In addition to the lack of correlation between baseline antibody titers of either species 138 with age and location, no correlations were found with the clinical manifestations of the disease. 139
While complicated brucellosis seems to be related with a lower antibody titer at baseline as given 140 by the significant P value, the correlation was considered null as it became insignificant when 141 the antibody titers were divided into two groups based on the cutoff value of ≥ 1:640. In both 142 cases, it should be noted that the correlation coefficient was low. 143
144

DISCUSSION 145
Brucellosis is an endemic disease common in Saudi Arabia, Iraq, Jordan, and other 146
Middle East countries, as well as Turkey, central Asia, Mexico, South America, and Asia-Pacific 147 region (8, 9) . As brucellosis is endemic, only few studies exist in the literature addressing the 148 condition, and studies concerning antibodies and their relationship with disease outcomes are 149 even scarce. Hence, this study aimed to fill the gap by assessing this relationship. 150
In a study of 116 clinically cured brucellosis patients, Almuneef, et al found that Brucella 151 antibodies remained detectable at end of therapy follow up despite full clinical recovery (7). 152 8 However, at a later time point after two years post completion of therapy, the antibody titers 153 decreased dramatically and reached undetectable levels in some patients. A similar finding was 154 seen in our patient population at EOT where about half of the patients who experienced clinical 155 success did not achieve the serological success of antibody titers of < 1:320. This fact is also 156 supported by the lack of correlation between the antibody titers and clinical outcomes, including 157 temperature and infection markers (WBC count, CRP level, and ESR). Nevertheless, it is 158 presumed that Brucella antibody titers of those patients would eventually reach undetectable 159 levels after 24 months or more after the EOT. 160
Our study also looked at the correlation of Brucella antibody titers with the clinical 161 picture of brucellosis including the most common symptom of arthralgia, as well as fever, 162 leukocytosis, and elevated inflammatory markers, CRP and ESR. A lack of correlation was 163 demonstrated between Brucella antibody titers and these variables. These results resemble the 164 findings from a study by Alsubaie and colleagues who evaluated the family members of 165 brucellosis patients whether they appeared symptomatic or asymptomatic (10) . Symptoms sought 166 in this study included arthralgia, fever, malaise, headache, anorexia, and weight loss. WBC 167 counts and inflammatory markers were not assessed. Forty of the 178 family members screened 168 for brucellosis had classic manifestations of the disease including arthralgia and fever, of whom 169 only 18 (45%) had positive serology results (≥ 1:160). Thus, they were confirmed to have acute 170 brucellosis (five had positive serology tests but claimed to have past infections). Such result 171 further confirms the lack of correlation between brucellosis symptoms and serology test for 172
Brucella as the remaining 55% symptomatic members had negative serology tests. This lack of 173 correlation was also observed when only four (3%) of 138 members had positive serology tests 9 despite absence of symptoms, hence they were diagnosed with the disease (seven had past 175 infections with positive serology results). 176
To our knowledge, this is the first study to evaluate the correlation between antibody 177 titers and culture positivity. Since our institution is located in an endemic country, patients are 178 serologically diagnosed with brucellosis when antibody titers measure 1:640 or higher. However, 179 when this criterion is not matched, a patient may still be diagnosed with the disease based on a 180 positive blood culture for Brucella or classic clinical picture of the disease. As demonstrated in 181 Baseline white blood cells count, cells/mm 3 (mean ± SD) 6.6 ± 4.9
Baseline C-reactive protein, mg/L (mean ± SD) 34.5 ± 39.9
Baseline erythrocyte sedimentation rate, mm/hr (mean ± SD) 29 ± 23. 
